This activity is expired and is no longer available for CME credit.


Prediction of 52-Week Treatment Response Based on a Week 12 Assessment in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison of a Patient-reported Instrument Versus Physician-based Disease Activity Assessment

Author(s)/Faculty: Jeffrey R. Curtis, MD, MPH, MS
Release Date: 12/29/2013Expiration Date: 12/28/2014
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: MultimediaProvider:
I'm here today to talk about a recently presented randomized control trial that randomized 733 Rheumatoid Arthritis patients that had failed at least one DMARD, or biologic, to management with either the rapid 3 disease activity measurement tool, or the CDAI disease activity tool...